ClinicalTrials.gg
RecruitingNCT07524972Updated Apr 13, 2026

Antenatal Magnesium Sulphate in High-Risk Preterm Patients

A Phase 3 interventional study of Magnesium sulfate and Placebo in Cerebral Palsy and Magnesium Sulfate Overdose, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Cairo University · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Cerebral Palsy by Cairo University — 28 open to participants now, 34 under way, 1 of them phase 3. Cerebral Palsy · Cairo University.

Planned enrollment
Largest of 94
138 · median 40
Started
2026
with 17 others
Phase 3
Only one
of the 114
Primary completion
2028-04
later than 33 of 33 live
Registered
99th of 114
by date

Among the 114 studies in Cerebral Palsy by Cairo University, this one has the largest planned enrollment of the 94 interventional ones that give a count, is one of 18 that started in 2026, is the only one in phase 3, reaches primary completion later than 33 of the 33 other live ones, and was the 99th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

28 of the 114 studies in Cerebral Palsy by Cairo University are open now, in 1 country. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 28 open studies →

Where they have run

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Cerebral Palsy by Cairo University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of cerebral palsy without causing significant maternal or neonatal adverse effects. Researchers will compare magnesium sulphate with a placebo in women at high risk of preterm birth between 32 and 35 weeks of gestation. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo before delivery, and maternal and neonatal outcomes will be followed after birth, including neurodevelopmental assessment of the infant.

Read the detailed description

Preterm birth is strongly associated with adverse neonatal outcomes, including cerebral palsy, which remains one of the most important long-term neurodevelopmental complications among preterm infants. Antenatal magnesium sulphate has been proposed as a fetal neuroprotective therapy because of its potential to reduce neuronal injury through anti-inflammatory, anti-excitotoxic, and membrane-stabilising effects. Although previous trials and systematic reviews support its neuroprotective role, further evaluation is needed in women at high risk of preterm delivery to assess its effectiveness and safety in routine obstetric practice.

This study is a randomised, placebo-controlled clinical trial conducted at Suez Canal University Hospital. Eligible pregnant women at high risk of preterm birth between 32 and 35 weeks of gestation, in whom delivery is planned or expected within 24 hours, will be randomised to receive either intravenous magnesium sulphate or placebo. The magnesium sulphate regimen consists of a loading dose followed by a maintenance infusion for up to 24 hours or until delivery. The placebo group will receive an isotonic sodium chloride solution administered in the same volume and schedule. Allocation concealment and blinding procedures are used so that participants and outcome assessors remain unaware of treatment assignment.

All participants will receive standard obstetric and neonatal care in addition to the assigned study treatment. Maternal monitoring during infusion will include clinical assessment and observation for adverse effects. Neonatal follow-up will include routine postnatal assessment and cranial ultrasound screening when indicated. Infants will undergo follow-up after discharge, with neurodevelopmental evaluation at corrected age to assess for cerebral palsy. The trial is designed to determine whether antenatal magnesium sulphate provides fetal neuroprotection in women at risk of preterm birth while maintaining acceptable maternal and neonatal safety.

03

Conditions studied

  • Cerebral Palsy
  • Magnesium Sulfate Overdose

Keywords

  • Antenatal
  • Magnesium Sulphate
  • Preterm
  • cerebral palsy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women at high risk of preterm birth between 32 and 35 weeks of gestation

    • Birth is planned or expected within 24 hours
    • Singleton pregnancy
    • No to antenatal magnesium sulphate
    • Able to provide

Exclusion criteria

  • Higher-order multiple pregnancy

    • Received antenatal magnesium sulphate during the current pregnancy for hypertension or preeclampsia
    • Magnesium sulphate is required for treatment of preeclampsia
    • Second stage of labor
    • Respiratory rate less than 16 breaths per minute
    • Absent patellar reflexes
    • Urine output less than 100 mL in the previous 4 hours
    • Renal failure
    • Hypocalcemia
    • Myasthenia gravis
    • Magnesium sulphate infusion had to be stopped because of adverse effects
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Magnesium Sulphate

    Participants in this arm will receive intravenous magnesium sulfate for fetal neuroprotection, given as a 4 g loading dose (8 mL) over 20 minutes followed by a maintenance infusion of 1 g/hour (2 mL/hour) until delivery or for up to 24 hours.

    Drug: Magnesium sulfate

  • Placebo comparator
    Placebo

    Participants in this arm will receive placebo as isotonic sodium chloride 0.9%, given intravenously as 8 mL over 20 minutes followed by a maintenance infusion of 2 mL/hour until delivery or for up to 24 hours, using the same schedule as the active treatment arm.

    Drug: Placebo

Interventions

  • Intravenous magnesium sulphate administered for fetal neuroprotection in women at high risk of preterm birth. Treatment is given as a loading dose followed by continuous maintenance infusion, with maternal monitoring during administration. The intervention is used for neuroprotection and not for tocolysis.

    Also known as: MgSO₄

  • DrugPlacebo

    Intravenous placebo infusion using isotonic sodium chloride 0.9%, administered in the same volume and schedule as the active treatment to maintain blinding. Maternal monitoring during infusion is performed in the same manner as in the active treatment group.

    Also known as: Isotonic sodium chloride 0.9%, Normal saline

06

What researchers measure

Primary outcomes

  1. Combined incidence of death or cerebral palsy

    Composite outcome defined as stillbirth, neonatal mortality, or cerebral palsy diagnosed by corrected age follow-up assessment. Cerebral palsy will be identified by a blinded pediatric and psychological assessment using established diagnostic criteria, including motor dysfunction or tone abnormalities.

    Time frame: By 6 months corrected age

Secondary outcomes

  1. Maternal side effects of magnesium sulphate

    Incidence of maternal adverse effects related to study treatment, including flushing, hypotension, and respiratory depression.

    Time frame: From the date and time of magnesium sulphate infusion initiation until hospital discharge, assessed up to 48 hours.

  2. Neonatal morbidity

    Incidence of neonatal morbidity including intraventricular hemorrhage, periventricular leukomalacia, and respiratory distress syndrome

    Time frame: From birth through 4 weeks after birth, cranial ultrasound was assessed within 7 days after birth and repeated at 4 weeks after birth when clinically indicated.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported results will be shared. This will include baseline maternal characteristics, treatment allocation, maternal safety data, delivery data, neonatal outcomes, and follow-up data used for assessment of the primary and secondary outcomes, including cerebral palsy evaluation and other recorded maternal and neonatal outcomes. Personal identifiers will be removed before sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be available beginning 6 months after publication of the main study results and will remain available for 5 years.

Access criteria: Access will be provided to qualified researchers for scientifically sound research proposals. Requests should include a brief proposal, analysis plan, and institutional affiliation. Data will be shared after approval by the principal investigator and local ethics requirements and after signing a data access or data use agreement. Only de-identified data will be released.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Apr 2028, 23 months later.

Of 17 phase 3 interventional studies under Cerebral Palsy, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 13, 2026
StartEst.
May 1, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
May 30, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07524972
Lead sponsor
Cairo University
Responsible party
ahmed nagy shaker ramadan (Lecturer of obstetrics and gynecology, Cairo University) — Principal investigator
First posted
Apr 13, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

mohamed shaaban, MD
Contact
mshaaban@hotmail.com
+2010 05153911

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Sulfate

Start the discussion